Literature DB >> 15305980

Immunohistochemical localization of vascular endothelial growth factor receptors-1, -2 and -3 in human spinal cord: altered expression in amyotrophic lateral sclerosis.

W G M Spliet1, E Aronica, M Ramkema, A N Witmer, R O Schlingemann, J M B V de Jong, D Troost.   

Abstract

Vascular endothelial growth factor (VEGF) has recently been implicated in several neurological disorders. Apart from its prominent role in angiogenesis, VEGF has been shown to have direct effects on neuronal and glial cells through activation of different VEGF receptor (VEGFR) types. In the present study the expression patterns of VEGFR-1, -2 and -3 were investigated in the spinal cord of control and both sporadic and familial amyotrophic lateral sclerosis (ALS) patients. Immunocytochemical analysis of control human spinal cord demonstrated that VEGFR-1, but not VEGFR-2 or -3 was found to be present in blood vessels of both white and grey matter. All three VGEFRs were not detectable in resting glial cells of control tissue. Diffuse neuropil staining was observed in the control spinal cord grey matter for VEGFR-3. Regional differences in VEGFRs immunoreactivity (IR) were apparent in ALS compared to controls. In particular, VEGFR-1 expression was increased in reactive astroglial cells in both grey (ventral horn) and white matter of ALS spinal cord. In addition to the astroglial labelling, increased expression of VEGFR-1 and, to a less extent also of VEGFR-2, was observed in blood vessels of the ALS spinal cord. No changes in VEGFR-3 IR were detected in blood vessels or reactive astroglial cells, whereas VEGFR-3 neuropil expression was reduced and paralleled the distribution of neuronal loss in the ventral horn of ALS spinal cord. These findings indicate that VEGFRs have specific distribution patterns, suggesting different physiological functions in human spinal cord. Moreover, the altered expression observed in ALS supports a role for these receptors in the complex reactive processes that are associated with the progression of spinal cord damage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15305980     DOI: 10.1111/j.1365-2990.2003.00543.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  5 in total

1.  Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression.

Authors:  Maureen M Tedesco; Masahiro Terashima; Francis G Blankenberg; Zoia Levashova; Joshua M Spin; Marina V Backer; Joseph M Backer; Mien Sho; Eiketsu Sho; Michael V McConnell; Ronald L Dalman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-02       Impact factor: 8.311

2.  TDP-43 Vasculopathy in the Spinal Cord in Sporadic Amyotrophic Lateral Sclerosis (sALS) and Frontal Cortex in sALS/FTLD-TDP.

Authors:  Isidro Ferrer; Pol Andrés-Benito; Margarita Carmona; Abdelilah Assialioui; Mónica Povedano
Journal:  J Neuropathol Exp Neurol       Date:  2021-02-22       Impact factor: 3.685

3.  Elevated Cerebrospinal Fluid Proteins and Albumin Determine a Poor Prognosis for Spinal Amyotrophic Lateral Sclerosis.

Authors:  Abdelilah Assialioui; Raúl Domínguez; Isidro Ferrer; Pol Andrés-Benito; Mónica Povedano
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

4.  Cellular distribution of vascular endothelial growth factor A (VEGFA) and B (VEGFB) and VEGF receptors 1 and 2 in focal cortical dysplasia type IIB.

Authors:  Karin Boer; Dirk Troost; Wim G M Spliet; Peter C van Rijen; Jan A Gorter; Eleonora Aronica
Journal:  Acta Neuropathol       Date:  2008-03-04       Impact factor: 17.088

Review 5.  ALS and oxidative stress: the neurovascular scenario.

Authors:  Akshay Anand; Keshav Thakur; Pawan Kumar Gupta
Journal:  Oxid Med Cell Longev       Date:  2013-12-03       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.